Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | S1PR2 | O95136 | 6/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.41 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807748 | 1.00 | CA2 (0.48) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL4902507 | 0.98 | CA2 (0.47) | CA2CA1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6802942 | 0.91 | S1PR2 (0.52) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8186793 | 0.91 | S1PR2 (0.52) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL28617729 | 0.91 | S1PR2 (0.52) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL6802283 | 0.90 | S1PR2 (0.50) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL6807996 | 0.90 | S1PR2 (0.50) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| Hydrochloric Acid SCHEMBL6797823 | 0.90 | S1PR2 (0.50) | ALDH1A1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL5206524 | 0.86 | — | — | |
| SCHEMBL288356 | 0.82 | S1PR2 (0.57) | CA2CA1SLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357918-A1 | NOVEL PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-08-08 | — | — | EP | claimed |
| EP-2928881-B1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-03-14 | — | — | EP | claimed |
| US-9522886-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-12-20 | — | — | US | claimed |
| US-20150307452-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | claimed |
| EP-2928881-A1 | NOVEL PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | claimed |
| WO-2014086705-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | claimed |
| EP-3357918-A1 | NOVEL PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| EP-2928881-B1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-03-14 | — | — | EP | disclosed |
| CN-107674061-A | Pyridine derivate | 霍夫曼-拉罗奇有限公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-104837831-B | Novel pyridine derivatives | 霍夫曼-拉罗奇有限公司 | 2017-10-31 | — | — | CN | disclosed |
| US-9522886-B2 | Pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20150307452-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2928881-A1 | NOVEL PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| CN-104837831-A | Novel pyridine derivatives | HOFFMANN LA ROCHE | 2015-08-12 | — | — | CN | disclosed |
| WO-2014086705-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| US-7608723-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-1H-benzimidazol-2-yl)-2-methylpropyl]-4-chlorobenzamide;kinesin spindle protein modulators; anticarcinogenic agents; in vivo stability, bio-availability; diagnosis/medical/;antitumor agents hyperplasia; restinosis; antiinflammatory agents; cardiac hypertrophy | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| EP-0747381-B1 | CARBAPENEM DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-5707987-A | BACTERICIDE ANTIBIOTICS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-01-13 | — | — | US | disclosed |
| EP-0747381-A1 | CARBAPENEM DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307452-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS3, NDUFV2 | CA2 2919/4885CA1 3915/4885SLC1A3 2381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.